Special Issue of AJMC on HCV: Access, Value, and Cost of Innovative Therapies

In a special issue of The American Journal of Managed Care (AJMC) on the Hepatitis C virus, released May 2016, IVI authors take up multiple key issues at the intersection of access, cost, and value from recent innovations in HCV treatment in four separate articles: “Does Patient Cost Sharing for HCV Drug Make Sense?" authored by Darius Lakdawalla, [...]

2017-07-18T22:08:06+00:00May 3rd, 2016|Research|

Measuring the Value of Prescription Drugs

Escalating drug prices have alarmed physicians and the American public and led to calls for government price controls. Less visibly, they have also spawned a flurry of private-sector initiatives designed to help physicians, payers, and patients understand the value of new therapies and thus make better choices about their use. Programs recently introduced or advanced [...]

2017-07-03T23:14:37+00:00December 31st, 2015|Publications, Research|

The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations

The PRISMA statement is a reporting guideline designed to improve the completeness of reporting of systematic reviews and meta-analyses. Authors have used this guideline worldwide to prepare their reviews for publication. In the past, these reports typically compared 2 treatment alternatives. With the evolution of systematic reviews that compare multiple treatments, some of them only [...]

2017-07-03T23:12:54+00:00June 2nd, 2015|Publications, Research|

Reforming Medicare’s Dialysis Payment Policies: Implications for Patients with Secondary Hyperparathyroidism

Expanding services covered by a “bundled payment” can also expand variation in the costs of treating patients under the bundle. In this article, Charu Gupta et al.explore this topic further using the Medicare dialysis program as an example. Source: Health Services Research

2017-07-03T23:01:17+00:00July 14th, 2014|Publications, Research|

Reforming Medicare’s Dialysis Payment Policies: Implications for Patients with Secondary Hyperparathyroidism

Expanding services covered by a “bundled payment” can also expand variation in the costs of treating patients under the bundle. In this article, Charu Gupta et al.explore this topic further using the Medicare dialysis program as an example. Source: Health Services Research

2017-07-03T23:16:18+00:00July 7th, 2014|Publications, Research|

Indirect Treatment Comparison/Network Meta-Analysis Study Questionnaire to Assess Relevance and Credibility to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report

Despite the great realized or potential value of network meta-analysis of randomized controlled trial evidence to inform health care decision making, many decision makers might not be familiar with these techniques. The Task Force developed a consensus-based 26-item questionnaire to help decision makers assess the relevance and the credibility of indirect treatment comparisons and network [...]

2017-07-03T22:31:22+00:00March 15th, 2014|Publications, Research|

Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers.

In the last decade, network meta-analysis of randomized controlled trials has been introduced as an extension of pairwise meta-analysis. The advantage of network meta-analysis over standard pairwise meta-analysis is that it facilitates indirect comparisons of multiple interventions that have not been studied in a head-to-head fashion. Although assumptions underlying pairwise meta-analyses are well understood, those [...]

2017-07-04T17:58:07+00:00July 4th, 2013|Publications, Research|

Meta-regression Models to Address Heterogeneity and Inconsistency in Network Meta-analysis of Survival Outcomes

Recently, network meta-analysis of survival data with a multidimensional treatment effect was introduced. With these models the hazard ratio is not assumed to be constant over time, thereby reducing the possibility of violating transitivity in indirect comparisons. However, bias is still present if there are systematic differences in treatment effect modifiers across comparisons. It was [...]

2017-07-03T22:35:22+00:00October 8th, 2012|Publications, Research|

Accounting for Correlation in Network Meta-analysis with Multi-arm Trials

Multi-arm trials are particularly valuable forms of evidence for network meta-analysis (NMA). Trial results are available either as arm-level summaries, where effect measures are reported for each arm or as contrast-level summaries, where the differences in effect between arms compare with the control arm chosen for the trial. We show that likelihood-based inference in both [...]

2017-07-03T22:38:45+00:00July 20th, 2012|Publications, Research|